Joel Schlessinger M.D.

Joel Schlessinger MD recently administered a study at the Advanced Skin Research Center that investigates the use of abobotulinumtoxinA, a new botulinum neurotoxin type A formulation, to treat moderate to severe glabellar lines in adults younger than 65 years. The results were published in the October 2011 issue of Dermtologic Surgery in the article, “Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.”

In this study, Joel Schlessinger MD administered 50 to 80 units of abobotulinumntoxinA or placebo at five injection sites in the glabellar region on study participants. The participants then self-evaluated their results and recorded the first effects.

On the first day, participants that received the abobotulinumntoxinA injection noticed a 13.4% to 32.5% improvement compared to 3% to 7% improvement as seen by those that received the placebo. It was concluded that use of abobotulinumntoxinA demonstrated a significant reduction in glabellar lines with improvement showing in as early as 24 hours with a median time of 3 days.

What is your experience using abobotulinumntoxinA to treat glabellar lines? Tell us about it in the comments.